Treatment of Metastatic Melanoma:
Updates from the Society for Melanoma Research 2014 International Congress
This CME certified enduring material is jointly provided by the Center for Continuing and Outreach Education at Rutgers Biomedical and Health Sciences and ASiM.
Supported by educational grants from Bristol-Myers Squibb Company and Prometheus Laboratories Inc.
Management of patients with advanced melanoma has evolved rapidly over the past few years resulting in significant changes in overall treatment paradigms. Recently, novel targeted therapies and immunotherapies have been approved, which offer additional treatment options to patients with unresectable or advanced melanoma. Various chemotherapies used in certain circumstances are also under investigation for use in combination with newer therapies. There is also continued development of genetic and immune response markers that can be predictive or prognostic indicators that allow clinicians to determine the most optimal therapy for individual patients. This online expert panel discussion, based on the latest data presented at the Society for Melanoma Research 2014 International Congress, is designed to educate healthcare professionals who care for patients with advanced and metastatic melanoma and will highlight advances in therapeutic options and the knowledge of how best to integrate these new therapies into clinical practice. A thorough understanding of the differences between targeted and immunotherapies and how patients respond to these treatments will be highlighted and discussed.
This educational activity will provide clinicians with up-to-date information on current trends in the treatment and management of patients with advanced metastatic melanoma.
This activity is designed for oncologists, surgical oncologists, nurse practitioners, physicians’ assistants, and other healthcare professions who care for patients with advanced melanoma. No prerequisites required.
Upon completion of this activity, participants should be better able to:
- ANALYZE current evidence-based data on new and emerging treatment options for metastatic melanoma.
- DESCRIBE the role of immunotherapy in the treatment of metastatic melanoma.
- INTEGRATE emerging treatment protocols in advanced/metastatic melanoma into community practice.
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Rutgers, The State University of New Jersey and ASiM.
Rutgers, The State University of New Jersey is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Rutgers, The State University of New Jersey designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
William Sharfman, MD, FACP (Course Director)
Associate Professor of Oncology and Dermatology
Johns Hopkins University School of Medicine
Director of Cutaneous Oncology
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Rene Gonzalez, MD
Professor of Medicine
Director, Melanoma Research Clinics
University of Colorado Comprehensive Cancer Center
Jeffrey Weber, MD, PhD
Senior Member, Moffitt Cancer Center
Director, Donald A. Adam Comprehensive Melanoma Center
In accordance with the disclosure policies of Rutgers and to conform with ACCME and FDA guidelines, individuals in a position to control the content of this educational activity are required to disclose to the activity participants: 1) the existence of any relevant financial relationship with any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients, with the exemption of nonprofit or government organizations and non-health care related companies, within the past 12 months; and 2) the identification of a commercial product/device that is unlabeled for use or an investigational use of a product/device not yet approved.
Dr Sharman has disclosed the following relevant financial relationships: Receiving grants/research support from Bristol-Myers Squibb Company; and serving as a consultant for Castle Biosciences Inc, Genentech Inc, and Merck & Co Inc.
Dr Gonzalez has disclosed the following relevant financial relationships: Receiving grants/research support from Amgen Inc, Bristol-Myers Squibb Company, Novartis, Merck & Co Inc, and Roche/Genentech Inc; and serving as a consultant for and serving on an advisory board for Amgen Inc and Roche/Genentech Inc.
Dr Weber has disclosed the following relevant financial relationships: Receiving grants/research support from and serving as a consultant for Bristol-Myers Squibb Company, Genentech Inc, GlaxoSmithKline, and Merck & Co Inc; receiving grants/research support from MacroGenics Inc; serving as a consultant for CytomX Therapeutics and Immune Design; and for serving on an advisory board for Altor, cCAM, Celldex Therapeutics, Ichor, Immune Design, and Pieris Pharmaceuticals Inc.
In order to help ensure content objectivity, independence, and fair balance, and to ensure that the content is aligned with the interest of the public, CCOE has resolved all potential and real conflicts of interest through content review by a non-conflicted, qualified reviewer. This activity was peer-reviewed for relevance, accuracy of content and balance of presentation by Ann W. Silk, MD, MS, Medical Oncologist, Rutgers Cancer Institute of New Jersey; Assistant Professor of Medicine, Division of Medical Oncology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ.
Dr Silk has no relevant financial relationships to disclose.
This activity was pilot-tested for time required for participation by Aleksander Chojecki, MD, Mendel Goldfinger, MD, and Kristen R. Spencer, DO, MPH.
Dr Chojecki, Dr Goldfinger and Dr Spencer, have no relevant financial relationships to disclose.
CCOE Staff: Patrick Dwyer, Director, Continuing Medical Education, has no relevant financial relationships to disclose.
ASiM Staff: Director, CE Accreditation, Melinda Ciattarelli; Medical Director, Jayashree Gokhale, PhD; and Executive Vice President, Daniel Guinee, MBA, CHCP, have no relevant financial relationships to disclose.
This activity contains information of commercial products/devices that are unlabeled for use or investigational uses of products not yet approved. This activity discusses the off-label use of the following approved agents: Dabrafenib, cobemetinib, ipilimumab, nivolumab, vemurafenib, trametinib, and pembrolizumab.
The estimated time to complete this activity: 90 minutes.
Release Date: September 24, 2015. Expiration Date: September 24, 2016.
The views expressed in this activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of any manufacturer of pharmaceuticals or devices, Rutgers, or ASiM. It should be noted that the recommendations made herein with regard to the use of therapeutic agents, varying disease states, and assessments of risk, are based upon a combination of clinical trials, current guidelines, and the clinical practice experience of the participating presenters. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult all available data on products and procedures before using them in clinical practice.
Copyright© 2015 Rutgers, The State University of New Jersey and ASiM. All rights reserved including translation into other languages. No part of this activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval systems, without permission in writing from Rutgers.
Please direct content or CE related questions or concerns to CCOE at 973-972-4267 or email email@example.com.
Please contact ASiM at 908-253-9001 or firstname.lastname@example.org.
There is no fee for participating in this activity.
Pentium 800 processor or greater, Windows 98/NT/200/XP or Mac OS 9/X or later, Microsoft Internet Explorer, Safari, Firefox, Windows Media Player 9.0 or later Flash player, 128 MB of RAM Monitor settings: High color at 800 x 600 pixels, sound card and speakers, Adobe Acrobat Reader.
Please complete the preassessment, listen to and view the following activity, and complete the postassessment and evaluation to receive CME credit for this activity. A statement of credit will be available online immediately following successful completion of the activity.
Treatment of Metastatic Melanoma: Changing Paradigms
William Sharfman, MD, FACP
Targeted Therapy in the Treatment of Metastatic Melanoma
Rene Gonzalez, MD
Immunotherapy in the Treatment of Metastatic Melanoma
Jeffrey Weber, MD